Atilla Yıldırım

8PUBLICATIONS
157CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

|Jun 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|Mar 28, 2026
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Sedat Yıldız, Hacer Demir, Talha Özüdoğru

|Mar 26, 2026
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu

|Nov 27, 2025
Altered Apoptosis in Endometriosis Compared with Ovarian Carcinoma.

Ozgur Ozdemir, Atila Yildirim, Yavuz Tekelioglu

Pageof 2

Frequent Collaborators

4 joint publications

Elif Şahin

4 joint publications

Esra Aşık

3 joint publications

Sedat Biter

3 joint publications

Ertugrul Bayram